![]() |
市场调查报告书
商品编码
1854892
眼表面疾病调查报告(2025年)2025 Ocular Surface Disease Survey Report |
||||||
Market Scope 于 2025 年 7 月至 8 月期间,对美国和西欧的眼科医生和验光师进行了调查,以了解他们接诊的患者情况、眼表疾病筛检、治疗方案的采用情况以及最新的市场趋势。
我们邀请了在 market-scope.com 网站上註册的眼科公司和涵盖大多数专科(白内障、屈光不正、视网膜、干眼症/青光眼和普通眼科)的验光师参与我们这项年度赞助调查。
我们于 2025 年 7 月 25 日发出邀请,并于 8 月 8 日最终联繫了受访者。我们收到了来自美国 158 位受访者和澳洲 40 位受访者的回复,共 198 位受访者。所有结果均以受访者人数计算。并非所有问题都适用于所有供应商,因此受访者人数 (n) 可能在整个调查过程中有所变化。
本调查报告仅为所报告数据的总结分析,并不试图推断整个市场的情况。所有调查资料均已匿名化处理,并储存于安全伺服器上。
本调查中的问题由 MarketScope 与本调查的赞助商合作制定。问题包括但不限于:
Market Scope surveyed ophthalmologists and optometrists in the US and Western Europe (WE) during July and August 2025 to measure patients they were seeing and screening for ocular surface disease; adoption of treatments; and insight into the latest market trends.
Ophthalmologists and optometrists from most specialties (cataract, refractive, retina, dry eye glaucoma, and comprehensive) who self-registered on market-scope.com were invited to participate in the annual sponsored survey.
An email invitation was sent on July 25, 2025, and a last call went out on Aug. 8, 2025. We received 198 total complete, unique responses - 158 from the US and 40 from WE. All results were calculated based on respondent count; because not all questions were applicable to all providers, the respondent count (n) may vary throughout the survey.
Survey reports are strictly a summary analysis of the reported data, and no additional extrapolation to the overall market was performed. All survey data are de-identified and maintained on a secure server.
Questions included in the survey were developed by Market Scope in combination with companies that sponsor the survey. Question topics included, but were not limited to, the following: